Quick Heal Technologies Limited (QUICKHEAL)
₹148.68 +3.34% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Quick Heal's revenue was ₹45.0 Cr (-21.4% year on year, -8.2% on the previous quarter), and net profit ₹-5.3 Cr (a smaller loss than a year earlier); the operating margin was -39.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹45.0 | -21.4% | -8.2% |
| Operating profit | ₹-17.6 | loss widened | loss narrowed |
| Net profit | ₹-5.3 | loss narrowed | loss narrowed |
| EPS (₹) | -0.94 | loss narrowed | loss narrowed |
| Operating margin | -39.1% | — | — |
QUICKHEAL delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 12.61% of the QUICKHEAL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 45.47%. The price rose 3.34% on unusually low delivery, so more of the move than usual was intraday trading. It traded 3.0 times its average daily volume.
Delivery in the last 5 sessions: 59.4% · 62.3% · 9.9% · 27.4% · 12.6%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Quick Heal Technologies Limited submitted the Scrutinizer's Report and voting results for its 31st Annual General Meeting held on September 23, 2026. All four resolutions were passed with more than 99.9% majority of votes cast, including the adoption of FY26 financial statements and director appointments. Out of 54,273,580 total outstanding shares, 39,052,529 shares (71.955%) were polled. This is a standard statutory outcome with no operational or financial surprises.
- All 4 resolutions approved with over 99.96% votes cast in favor
- Total voter turnout represented 71.955% of outstanding shares (39,052,529 votes polled out of 54,273,580 shares)
- Adoption of FY26 standalone and consolidated financial statements passed with 99.9995% approval
- Re-appointment of Mr. Richard Stiennon as Non-Executive Independent Director passed as a special resolution with 99.9655% approval
- Total shareholder base stood at 63,195 as of the record date (September 17, 2026)
Quick Heal Technologies announced that Mr. Sudhanshu Tripathi has resigned from his position as Chief Marketing Officer (Senior Management Personnel) effective September 16, 2026. The executive stepped down to pursue external opportunities aligned with his professional growth. The company is currently experiencing business pressure, reporting a TTM net loss of Rs 11 Cr and an operating loss of Rs 17.57 Cr in Q1 FY27 (June 2026). Quick Heal has not yet announced a successor for the CMO position.
- Chief Marketing Officer Sudhanshu Tripathi resigned effective September 16, 2026
- Departure is classified under Senior Management Personnel pursuant to Regulation 30
- Reason cited for departure is pursuit of career aspirations and professional growth
- Company posted TTM net losses of Rs 11 Cr on TTM revenue of Rs 249 Cr
Quick Heal Technologies Limited has announced the resignation of its Chief Marketing Officer (Senior Management Personnel), Sudhanshu Tripathi, effective September 16, 2026. The departure is attributed to pursuing professional growth and other career aspirations. This management exit comes at a time when Quick Heal is transitioning from stagnant consumer cybersecurity to enterprise security (Seqrite), against a backdrop of TTM losses of Rs 11 Cr and FY26 revenue of Rs 261.29 Cr.
- Resignation of Sudhanshu Tripathi from the position of Chief Marketing Officer
- Cessation is effective immediately from September 16, 2026
- Reason cited in the resignation letter is professional growth and long-term career aspirations
- Company reported TTM revenue of Rs 249 Cr and an operating loss margin of -14.8%
Quick Heal Technologies has submitted a clarification to the National Stock Exchange regarding a recent significant spurt in trading volume. The company confirmed that it has fulfilled all disclosure requirements under Regulation 30 of SEBI LODR Regulations, 2015, and has not withheld any material events or information. Quick Heal clarified that the trading volume surge is purely driven by market forces and general market conditions beyond its control.
- Clarification issued in response to NSE surveillance query letter dated September 15, 2026
- Company confirmed compliance under Regulation 30 of SEBI LODR Regulations, 2015
- No undisclosed price-sensitive information or material corporate developments reported
- Filing officially signed and submitted on September 16, 2026
Quick Heal Technologies Limited has confirmed the cessation of Mr. Samuel Sathyajith as Senior Vice President - Enterprise Sales, effective September 4, 2026, following his resignation letter dated August 11, 2026. The departure comes at a crucial juncture as Quick Heal pivots toward its enterprise arm (Seqrite), which contributes approximately 44% of gross revenue. The company reported TTM revenue of Rs 249 Cr and a TTM net loss of Rs 11 Cr, making enterprise sales execution critical to returning to operating profitability.
- Cessation of Mr. Samuel Sathyajith as Senior Vice President - Enterprise Sales effective September 4, 2026
- Formal resignation was submitted on August 11, 2026, citing pursuit of the next phase of his career
- Enterprise division (Seqrite) accounts for ~44% of company gross revenue
- Company posted an operating loss of Rs 17.57 Cr in Q1 FY27 (Jun 2026)
Quick Heal Technologies Limited has issued and allotted 9,746 equity shares of face value ₹10 each under its ESOP Scheme 2021. The exercise prices for the allotment were ₹114, ₹119, and ₹122 per share. Following this allotment, the company's total issued share count increased to 5,42,73,580 equity shares, representing a total paid-up share capital of ₹54,27,35,800. The dilution impact on existing shareholders is negligible at under 0.02%.
- Allotment of 9,746 equity shares of face value ₹10 each under ESOP Scheme 2021
- Exercise prices set at ₹114, ₹119, and ₹122 per share
- Total issued share capital expands to ₹54,27,35,800 divided into 5,42,73,580 equity shares
- New shares rank pari-passu with existing equity shares
Quick Heal Technologies Limited has appointed Mr. Amit Chaudhary as Vice President - Product Management and Senior Management Personnel, effective September 01, 2026. Mr. Chaudhary brings over 26 years of experience in IT and Telecom, specializing in Cybersecurity, Cloud, and Enterprise Networking. He previously led Bharti Airtel's Cyber Security & Cloud business, scaling it to ₹600 Cr ARR with a team of over 450 professionals. The appointment aligns with Quick Heal's strategic focus on expanding its Enterprise segment (Seqrite).
- Appointed Mr. Amit Chaudhary as Vice President – Product Management w.e.f. September 01, 2026.
- Brings over 26 years of industry experience across Cyber Security, Cloud, and Enterprise Networking.
- Previously scaled Bharti Airtel's Cyber Security & Cloud business to ₹600 Cr ARR managing 450+ professionals.
- Holds a PGDBM from IIM Kozhikode and a B.E. in Electronics & Communications from PICT.
Quick Heal Technologies Limited has issued an intimation under Regulation 30 and 36(1)(b) of SEBI LODR regarding the dispatch of physical letters to shareholders without registered email addresses. The letter provides the weblink to the Integrated Annual Report for FY 2025-26 and shares the AGM notice. The 31st Annual General Meeting (AGM) is scheduled to be held on September 23, 2026, at 11:30 AM IST via Video Conferencing.
- 31st Annual General Meeting scheduled for September 23, 2026, at 11:30 AM IST via VC/OAVM
- Cut-off date for dispatch of annual report intimation letters was August 21, 2026
- Dispatched weblink to FY26 Integrated Annual Report to shareholders without registered emails
- Reminded shareholders to complete mandatory KYC and nomination updation through RTA MUFG Intime India
Quick Heal Technologies Limited has issued the notice for its 31st Annual General Meeting (AGM) scheduled for September 23, 2026, via video conferencing. Key ordinary agenda items include the adoption of FY26 standalone and consolidated financial statements and the reappointment of Sanjay Katkar as a director retiring by rotation. Special business items include approving remuneration to Non-Executive Independent Directors for FY26 and reappointing Richard Stiennon as an Independent Director for a second 5-year term (2026-2031).
- 31st Annual General Meeting scheduled for Wednesday, September 23, 2026 at 11:30 AM IST via VC/OAVM
- Special resolution proposed for re-appointment of Mr. Richard Stiennon as Independent Director for a 5-year term from Sept 27, 2026 to Sept 26, 2031
- Ordinary resolution proposed for approval of remuneration/commission to Non-Executive Independent Directors for FY26
- Adoption of audited FY26 financial statements where Quick Heal reported annual revenue of Rs 261.29 Cr and a net loss of Rs 10.99 Cr
Quick Heal Technologies Limited has scheduled its 31st Annual General Meeting (AGM) for Wednesday, September 23, 2026, to be conducted via Video Conferencing/Other Audio Visual Means. The remote e-voting window opens on Saturday, September 19, 2026 (9:00 a.m. IST) and concludes on Tuesday, September 22, 2026 (5:00 p.m. IST). The record cut-off date to determine member voting eligibility has been fixed as September 17, 2026. The full AGM notice and Annual Report for FY2025-26 will be dispatched separately.
- 31st Annual General Meeting scheduled for September 23, 2026, via Video Conferencing
- Cut-off date for determining voting eligibility set as September 17, 2026
- Remote e-voting window opens September 19, 2026 (9:00 a.m. IST) and ends September 22, 2026 (5:00 p.m. IST)
- Annual Report for financial year 2025-26 and formal AGM Notice to be circulated separately
Quick Heal Technologies has approved the grant of 1,02,000 Employee Stock Options (ESOPs) under its 2021 Scheme. These options are exercisable into an equivalent number of equity shares at an exercise price of ₹76, which is a 50% discount to the NSE closing price on August 10, 2026. The vesting period is structured between 1 and 4 years, with an exercise window of 3 years post-vesting. This is a routine talent retention measure common in the technology sector.
- Grant of 1,02,000 options convertible into 1,02,000 equity shares of ₹10 face value each.
- Exercise price fixed at ₹76, representing a 50% discount to the market price as of August 10, 2026.
- Vesting schedule ranges from a minimum of 1 year to a maximum of 4 years from the grant date.
- Vested options must be exercised within 3 years from their respective vesting dates.
Quick Heal Technologies announced that Mr. Samuel Sathyajith, Senior Vice President - Enterprise Sales, has tendered his resignation on August 11, 2026, to pursue other professional opportunities. His last working day will be on or before September 4, 2026. This departure comes at a crucial juncture as Quick Heal pivots toward its Enterprise segment (Seqrite), which contributes approximately 44% of gross revenue. The company will announce the effective cessation date within regulatory timelines.
- Mr. Samuel Sathyajith resigned as Senior Vice President - Enterprise Sales on August 11, 2026
- Effective cessation date is scheduled on or before September 4, 2026
- Enterprise business (Seqrite) accounts for ~44% of gross revenue under the ongoing strategic pivot
- Departure stated as voluntary to pursue the next phase of his professional journey
Quick Heal Technologies has appointed Mr. Rajiv Sreekantan as Senior Vice President - Enterprise Sales, effective August 11, 2026. This high-profile hire from IBM (26-year tenure) is strategically aligned with the company's pivot toward its 'Seqrite' enterprise segment, which now contributes 44% of gross revenue. Given the company's TTM net loss of ₹11 Cr and declining annual revenue (₹261 Cr in FY26 vs ₹292 Cr in FY24), this leadership change is critical for scaling B2B sales and government contracts.
- Appointment of Rajiv Sreekantan as SVP - Enterprise Sales effective August 11, 2026
- Mr. Sreekantan brings 30+ years of experience, including 26 years at IBM leading Enterprise Storage for Hybrid Cloud & AI
- Enterprise segment (Seqrite) currently accounts for 44% of the company's gross revenue
- Company reported a TTM net loss of ₹11 Cr, emphasizing the need for high-impact sales leadership
- New appointee previously managed large-scale transformations for marquee clients like Reliance Jio
Quick Heal Technologies has announced the resignation of Mr. Samuel Sathyajith, Senior Vice President - Enterprise Sales, effective on or before September 4, 2026. This departure is significant as the company is currently pivoting its business model toward the Enterprise segment (Seqrite), which now contributes 44% of gross revenue. With a TTM revenue of ₹261 Cr and a net loss of ₹11 Cr, leadership stability in this growth-driving division is critical for the company's turnaround efforts. The stock has faced significant pressure, declining 47.3% over the last 12 months.
- Mr. Samuel Sathyajith to step down as SVP - Enterprise Sales by September 4, 2026.
- Enterprise segment (Seqrite) currently accounts for 44% of the company's gross revenue.
- Company reported a TTM net loss of ₹11 Cr against a TTM revenue of ₹261 Cr.
- EDR and XDR products constitute 90% of the enterprise revenue that the outgoing executive managed.
- Stock price has seen a 12-month return of -47.3% as of the announcement date.
Quick Heal Technologies reported a consolidated net loss of ₹5.28 Cr for Q1 FY27, compared to a loss of ₹5.51 Cr in the same period last year. Revenue from operations fell significantly by 21.4% YoY to ₹44.99 Cr, representing only 17% of TTM revenue. The bottom line was heavily supported by a one-time 'Other Income' of ₹14.10 Cr, which includes a ₹6.73 Cr service tax refund. Operationally, the company remains under pressure as employee benefit expenses of ₹43.20 Cr consumed nearly 96% of its operational revenue.
- Revenue from operations declined 21.4% YoY to ₹44.99 Cr from ₹57.23 Cr in Q1 FY26.
- Net loss narrowed slightly to ₹5.28 Cr from ₹5.51 Cr YoY, aided by non-operational income.
- Other income included a ₹6.73 Cr refund of service tax pre-deposits and related interest.
- Employee benefit expenses stood at ₹43.20 Cr, reflecting a high fixed-cost base relative to current revenue.
- Mr. Richard Stiennon re-appointed as Independent Director for a second 5-year term starting September 2026.
Financial Performance
Revenue Growth by Segment
In Q2 FY26, total net revenue grew 13.6% YoY to INR 83.5 Cr. The Enterprise segment (Seqrite) grew 30.0% YoY to INR 36.9 Cr, while the Consumer segment grew 8.3% YoY to INR 59.5 Cr. However, for H1 FY26, total net revenue declined 2.1% YoY to INR 140.8 Cr, with Consumer revenue falling 7.7% YoY to INR 91.2 Cr and Enterprise revenue rising 12.8% YoY to INR 68.6 Cr.
Geographic Revenue Split
Approximately 20% of Enterprise revenue is derived from International markets, with specific growth momentum noted in Southeast Asia and the Middle East. The remaining 80% of Enterprise and the bulk of Consumer revenue are domestic-focused, leveraging 'Make in India' positioning.
Profitability Margins
Gross margins remained exceptionally high at 96.9% in Q2 FY26 (compared to 96.3% in Q2 FY25). PAT margin for Q2 FY26 stood at 9.5% (INR 7.9 Cr), a significant recovery from a negative PAT margin of 9.6% (INR -5.5 Cr) in the immediate previous quarter (Q1 FY26).
EBITDA Margin
EBITDA margin for Q2 FY26 was 11.1% (INR 9.2 Cr), up from 4.2% (INR 3.1 Cr) in Q2 FY25, representing a 200.7% YoY increase in absolute EBITDA. This improvement was driven by seasonal strength in the consumer business and better operational efficiency through AI and automation in R&D.
Capital Expenditure
In FY25, the company invested INR 14.42 Cr in the purchase of property, plant, and equipment and intangible assets, compared to INR 7.56 Cr in FY24. This 90.7% increase reflects ongoing investments in infrastructure and product development.
Credit Rating & Borrowing
The company remains debt-free as of September 30, 2025, with a strong cash and investment balance of INR 191 Cr. This zero-debt status eliminates interest rate sensitivity on borrowings and provides flexibility for R&D and market expansion.
Operational Drivers
Raw Materials
As a software company, physical raw materials are minimal. 'Cost of material consumed' (primarily packaging/media for retail products) was INR 6.10 Cr in FY25, representing only 2.18% of total revenue. The primary operational cost is 'Employee benefits expense' at INR 185.55 Cr (66.4% of FY25 revenue).
Import Sources
Not specifically disclosed, but the company emphasizes its 'Make in India' status, suggesting high domestic value addition in its software development processes.
Key Suppliers
Not disclosed in available documents as the business model is driven by internal R&D rather than external raw material procurement.
Capacity Expansion
Operational capacity is measured by R&D and sales headcount rather than physical units. The company recently granted 48,000 ESOPs on November 28, 2025, to retain talent. R&D investments are being optimized through AI and automation to increase output without linear headcount growth.
Raw Material Costs
Direct costs (including material and software purchase) were INR 2.6 Cr in Q2 FY26, roughly 3.1% of revenue. The company maintains high gross margins by expensing all R&D investments (INR 32.9 Cr in Q2 FY26) rather than capitalizing them.
Manufacturing Efficiency
Efficiency is tracked via EBITDA margin improvement, which reached 11.1% in Q2 FY26 from a negative 17.0% in Q1 FY26, aided by seasonal tailwinds and cost optimization.
Logistics & Distribution
The company relies on a nationwide partner network. Sales and marketing expenses, which cover distribution support, were INR 22.5 Cr in Q2 FY26, or 26.9% of revenue.
Strategic Growth
Expected Growth Rate
13.60%
Growth Strategy
The strategy involves pivoting from the stagnant Consumer segment to the high-growth Enterprise segment (Seqrite), which now contributes 44% of gross revenue. Key drivers include the flagship EDR and XDR products (90% of enterprise revenue), new product launches like STI (Sentinel Threat Intelligence) and SMAP, and expanding the Government business where momentum is picking up with an order book of INR 27+ Cr.
Products & Services
Consumer cybersecurity software (Quick Heal), Enterprise security solutions (Seqrite), Endpoint Detection and Response (EDR), Extended Detection and Response (XDR), Data Privacy solutions, and Sentinel Threat Intelligence (STI).
Brand Portfolio
Quick Heal (Consumer), Seqrite (Enterprise).
New Products/Services
Recently launched STI (Sentinel Threat Intelligence) and SMAP. The company also received its first order for Seqrite Data Privacy in Q2 FY26. These newer products are expected to diversify the Enterprise revenue base beyond EDR/XDR.
Market Expansion
Focusing on International growth in Southeast Asia and the Middle East. In the domestic market, the company is targeting the 'Mid-Market' and 'SMB' segments for its Seqrite arm.
Market Share & Ranking
The company claims market leadership in the Indian consumer cybersecurity segment and is a 'premium' player.
Strategic Alliances
The company operates through a 'Strong Partner Network' across India to maintain proximity to customers and drive retail growth.
External Factors
Industry Trends
The industry is shifting toward platformized cybersecurity solutions (XDR/EDR) and Zero Trust architectures. Quick Heal is evolving from a pure-play antivirus provider to a holistic enterprise security partner to capture this 80% enterprise-heavy market (INR 3,200 Cr out of a total INR 4,000 Cr addressable market).
Competitive Landscape
Key competitors include global players like McAfee and various indigenous Indian cybersecurity firms. Quick Heal differentiates through premium pricing and local support proximity.
Competitive Moat
The moat is built on brand recognition in India, a 15-20% pricing premium, and a deep distribution network. Sustainability is supported by high switching costs in enterprise security and 'Make in India' certifications for government procurement.
Macro Economic Sensitivity
The business benefits from 'seasonal tailwinds' such as 'back-to-school' campaigns in the consumer segment. However, it is sensitive to general economic conditions affecting IT spending in the SMB and Enterprise sectors.
Consumer Behavior
There is a noted shift/headwind in the traditional consumer PC security market, prompting the company to focus more on Enterprise and newer digital privacy needs.
Geopolitical Risks
As a cybersecurity firm, it benefits from 'Make in India' and 'Atmanirbhar Bharat' initiatives, which reduce risks from international trade barriers in the sensitive government sector.
Regulatory & Governance
Industry Regulations
Operations are governed by SEBI (Share Based Employee Benefits) Regulations for ESOPs and the Companies Act 2013. Cybersecurity products must meet various international and domestic standards (e.g., AV-Test, AVLab Poland certifications).
Environmental Compliance
Not a major factor for software operations; the company files Business Responsibility and Sustainability Reporting as part of its annual requirements.
Taxation Policy Impact
The effective tax rate is impacted by deferred tax assets. In FY25, the company had a total tax benefit of INR 4.04 Cr despite a profit before tax of INR 1.00 Cr.
Legal Contingencies
The company has pending litigations disclosed in Note 35(d) of the consolidated financial statements. While specific values aren't in the summary, auditors noted these could impact the consolidated financial position.
Risk Analysis
Key Uncertainties
The primary uncertainty is the successful transition to the Enterprise segment to offset stagnant Consumer revenue. Consumer revenue declined 7.7% in H1 FY26, highlighting the urgency of this shift.
Geographic Concentration Risk
High concentration in the Indian market, although International revenue is trending positively in Southeast Asia and the Middle East.
Third Party Dependencies
Significant dependency on the 'Strong Partner Network' for collections and sales reach. Challenges in partner collections have directly impacted past revenue performance.
Technology Obsolescence Risk
High risk due to the rapidly evolving threat landscape. The company mitigates this by investing ~39% of revenue into R&D and launching products like XDR and Data Privacy.
Credit & Counterparty Risk
Provision for doubtful debts was INR 3.92 Cr in FY25 (down from INR 7.15 Cr in FY24), indicating ongoing but slightly improving credit risk management with partners.